Actovegin: diabetic neuropathy use — EA021189B1
Лусине Моусесьян · 2015 · EA021189B1 · patent family 41345991
Published 2015-04-30.
Reported patent results
Reported findings
Symptom scores favored Actovegin, while some neuropathy and quality-of-life endpoints were neutral. The patent is not independent replication of the journal trial.
Patent disclosure of the published Actovegin diabetic-neuropathy program: 569 randomized; treatment/ITT population 281 active and 286 placebo.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total Symptom Score: end-to-baseline change | −5.5 ± 2.6 versus −4.7 ± 2.9; adjusted difference −0.86 | Actovegin versus placebo · End of study · 95% CI −1.22 to −0.50; p<0.0001 |
| Time-averaged vibration threshold | Ratio 0.97 | Actovegin versus placebo · During treatment · 95% CI 0.94–1.00; p=0.084 |
| Lower-limb neuropathy score | Adjusted difference −0.48 | Actovegin versus placebo · End-of-study change · Table 5: p=0.080; CI −1.01 to 0.06. A later table inconsistently prints p=0.008. |
| Reported adverse events | 186 active versus 198 placebo events; serious events 10 in 7 active patients versus 11 in 10 placebo patients | Event counts are not numbers of affected patients |
Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The patent concerns a deproteinized hemoderivative and diabetic-neuropathy treatment, with clinical material in the disclosure.
Related trial publications and patent descriptions must not be counted as independent clinical replications.
- Publication
- EA021189B1 ↗ · 2015-04-30
- Earliest priority / filing
- 2008-09-29 / 2009-09-29
- Original applicant / assignee
- Такеда Австрия Гмбх
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41345991 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for prevention and treatment of diabetic peripheral neuropathy by a deproteinised hemoderivative
Inventors: Лусине Моусесьян.
EA021189B1 · EP2340026B1 · KR20110067054A · CN102264375A · GEP20135901B · WO2010034315A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Related trial publications and patent descriptions must not be counted as independent clinical replications.
- Patent tables contain OCR/sign and p-value inconsistencies; the repeated TSS contrast and its interval were cross-checked across tables. Neutral primary/secondary findings are retained and no independent-trial count is added.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-41345991. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Лусине Моусесьян. Actovegin: diabetic neuropathy use — EA021189B1 EA021189B1 · patent family 41345991 2015.
Molekul research summary: https://molekul.io/research/patent-ea021189b1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry